Asthma Resources
ERS 2022
Want to know more about the value of the ‘triple approach’ to treatment of severe asthma, and the important role anti-IgE continues to play in management?
Watch key highlights from two Novartis-sponsored symposiums from the European Respiratory Society (ERS) International Congress 2022, in Barcelona, Spain, held during September 2022.
- In “A triple approach to shifting the asthma paradigm: inhaled therapy, digital technology and the environment”, explore the key role inhaled therapy continues to play in asthma control, hear about exciting developments in digital technology, and learn about environmentally sustainable approaches for patients with asthma
- In “Asthma and beyond: Anti-IgE continues to play a major role”, take a deep dive into the clinical evidence behind the role of IgE in severe asthma, the latest evidence on the impact of anti-IgE treatment on aspects of disease control and progression, including real-world evidence and safety in pregnancy
A triple approach to shifting the asthma paradigm: inhaled therapy, digital technology and the environment
The Novartis-Sponsored symposium entitled “A triple approach to shifting the asthma paradigm: inhaled therapy, digital technology and the environment” at ERS 2022 was chaired by Professor Christine Jenkins from Australia, and included presentations and discussions with Professor Richard van Zyl Smit from South Africa, Dr Christopher Licskai from Canada, and Professor Ashley Woodcock from the UK.
The symposium commenced with a welcome and introductory presentation from chair Professor Jenkins, including the objectives of the symposium, the agenda, relevant disclosures. View the presentation below.
Shifting the paradigm with inhaled asthma therapy
In the first presentation of the symposium, Professor Richard van Zyl Smit from South Africa discusses the key role that inhaled therapies still have in achieving asthma control. Professor van Zyl Smit explores clinical trial evidence including new pivotal trials of LABA/LAMA/ICS, their impact on exacerbations, lung function and asthma control. He also explores the importance of adherence in asthma control. This presentation was followed by a Q&A session, including discussions on where inhaled therapies and biologics fit in the treatment pathway, and decisions about stepping up and stepping down treatment.
Click play to view this 30-minute presentation below. To skip to the Q&A, click on the video progress bar. Chapters are included at the following timepoints:
0:00–17:42 Presentation
17:43–end Q&A session
Shifting the paradigm with digital healthcare
Dr Christopher Licskai from Canada continued the symposium with a discussion of innovations in digital healthcare for asthma and chronic obstructive pulmonary disease (COPD) that can empower patients and HCPs. Dr Licskai defines and explains digital therapeutics focused on evidence-based digital health and medical devices such as smart inhalers, before exploring some specific studies in which these have been investigated. The presentation was followed by a Q&A discussion, in which the smartphones used in the studies, personalisation and real-world usage are discussed.
Click play to view this 25-minute presentation below. The skip to the Q&A, click on the video progress bar. Chapters are included at the following timepoints:
0:00-15:07 Presentation
15:08-end Q&A Session
Shifting the paradigm with environmental approaches
The final speaker in the symposium was Professor Ashley Woodcock from the United Kingdom, who presented on the environmental impact of asthma medications and more sustainable approaches. Professor Woodcock shared his perspective on the climate crisis and its devastating effect both to the planet generally and on our health. Regulations on hydrofluorocarbons (HFCs), the carbon footprint of inhalers and alternative approaches to asthma care were also discussed. The presentation was followed by a Q&A discussion on how HCP-patient communication, education and treatment choices could reduce environmental impact.
Click play to view this 25-minute presentation below. The skip to the Q&A, click on the video progress bar. Chapters are included at the following timepoints:
0:00-18:58 Presentation
18:59-end Q&A Session
Q&A and closing remarks
Finally, Christine Jenkins closed the session, summarising the three presentations and providing an overall conclusion.
Symposium agenda
The agenda for the Novartis-sponsored symposium, “A triple approach to shifting the asthma paradigm: inhaled therapy, digital technology and the environment” at ERS 2022 is provided below.
Session Agenda
| Topic | Speaker |
| Welcome and introduction | Chair – Professor Christine Jenkins (Australia) |
| Shifting the paradigm with inhaled asthma therapy • Presentation • Panel discussion with audience Q&A |
Professor Richard van Zyl Smit (South Africa) |
| Shifting the paradigm with digital healthcare • Presentation • Panel discussion with audience Q&A |
Professor Christopher Licskai (Canada) |
| Shifting the paradigm with environmental approaches • Presentation • Panel discussion with audience Q&A |
Professor Ashley Woodcock (UK) |
| Conclusion | Chair – Professor Christine Jenkins |
Asthma and Beyond: Anti-IgE continues to play a major role
This Novartis-sponsored symposium, “Asthma and beyond: Anti-IgE continues to play a major role” was held at ERS 2022 was chaired by Professor Celeste Michala Porsbjerg from Denmark, who was joined by Professor Oscar Palomares from Spain, Andrew Menzies-Gow from the UK, and Philippe Geveart from Belgium.
As the session opened, session chair Professor Porsbjerg provided a welcome and introductory presentation to kick off discussions on anti-IgE in asthma and associated comorbidities. To listen, click play below.
Why still target IgE pathways in the airways?
Professor Oscar Palomares highlights the central role of IgE in all the phases of allergic asthma, its role in nasal polyposis, and the effects of anti-IgE treatment with omalizumab. He also highlights research that indicates induction of regulatory T cells from treatment with omalizumab in vitro.
Click play to view this 15-minute presentation below. To skip to specific chapters of interest within the video, click on the video progress bar. Chapters are included at the following timepoints:
0:00–00:34 Introduction and disclosures
00:35–08:15 IgE in allergic asthma and nasal polyposis
08:16– 13:23 Biologics targeting IgE (omalizumab)
13:24– end Conclusion and summary
Why does anti-IgE remain important in the management of severe asthma?
Professor Andrew Menzies-Gow outlines the important role anti-IgE continues to play in management of severe asthma. He reviews key clinical evidence for the anti-IgE omalizumab on severe exacerbations and hospitalisations, asthma control, and its potential impact on clinical remission/disease modification. He also explores findings from real-world studies of omalizumab in clinical practice, findings from registry data on the safety profile of omalizumab in pregnancy, and closes with a discussion on the effect of omalizumab on the comorbidities of severe asthma.
Click play to view this 15-minute presentation below. Skip to specific chapters of interest by clicking on the progress bar within the video. Chapters are included at the following timepoints:
0:00–00:32 Introduction and disclosures
00:33–14:15 Clinical trial evidence for omalizumab, findings from real-world, follow-up and registry data and the impact of omalizumab on comorbidities of severe asthma
14:16–end Conclusion and summary
Why look beyond asthma? Anti-IgE in the treatment of co-morbidities
Join Professor Phillipe Geveart from the Ghent University Hospital in Belgium, as he explores clinical evidence for anti-IgE therapies in asthma comorbidities, including allergic rhinitis, chronic sinusitis with nasal polyps (CRSwNP), and allergic fungal rhinosinusitis.
Q&A
Watch the video clip below to listen to the Q&A session, in which the experts discussed the potential for viral infection to drive asthma exacerbations, and the currently understanding of the optimal duration of biologic treatment.
Symposium agenda
The agenda for the Novartis-sponsored symposium, “Asthma and beyond: Anti-IgE continues to play a major role” at ERS 2022 is provided below.
| Topic | Speaker |
| Welcome and introduction | Celeste Porsbjerg |
| Why still target IgE pathways in the airways? | Oscar Palomares |
| Why does anti-IgE remain important in the management of severe asthma? | Andrew Menzies-Gow |
| Why look beyond asthma? Anti-IgE in the treatment of comorbidities | Philippe Geveart |
| Q&A (live and online) | All |
| Summary and close | Celeste Porsbjerg |
Inhaled therapy science: a step forward in asthma
Welcome to Part 1 of the Novartis-sponsored symposium ‘Inhalation science and climate change: a step forward in asthma’. Part 2 can be viewed in the Sustainability section here.
In Part 1, ‘Inhaled therapy science: a step forward in asthma’, leading experts Professor David Price (chair), Professor Christine Jenkins, Professor Ken Chapman and Professor Christopher Lacksai discuss current challenges in inhaled asthma therapies. Updates to the GINA 2021 management cycle are examined, as well as the latest evidence and key clinical data in inhaled therapies, including indacaterol/glycopyrronium/mometasone furoate. Finally, the panel discuss the latest in digital innovation in respiratory care. Each presentation is followed by a lively panel discussion from all the faculty. Content produced in September 2021.
| 00:00 | Welcome and introduction (David Price) |
| 02:26 | The management cycle: a major advance (Christine Jenkins) |
| 13:54 | Panel discussion |
| 22:04 | Stepping stones to asthma control: inhaled therapy science (Ken Chapman) |
| 33:54 | Panel discussion |
| 36:55 | Stepping stones to patient centricity: digital science (David Price, Christopher Licksai) |
| 47:08 | Panel discussion |
| 53:46 | Summary (David Price) |
The new reality – better asthma care supported by digital health solutions (ERS 2020)
Using innovative Holopresence technology to provide a sense of real presence, we are pleased to bring you this exciting Novartis-sponsored symposium highlighting current and potential digital solutions to unmet needs with inhaled asthma therapies. The panel comprising Professor David Price (chair), Professor Kostantinos Kostikas and Dr Holger Woehrle discuss how digital innovations are currently being used for better informed decision-making and patient support.
Introduction
Professor David Price (Singapore) welcomes us to the symposium, introduces his co-presenters and provides an overview of the agenda
Digital solutions to real world challenges: addressing unmet needs with digital technology
Professor Price highlights the ongoing burden of asthma and COPD and describes the challenges of achieving good inhaler technique and adherence. He introduces digital solutions to these challenges such as telehealth and electronic sensor devices, which fit onto patients’ inhalers to monitor inhaler use.
Digital innovation: supporting the progress of asthma management
Professor Kostantinos Kostikas (Greece) provides an overview of digital solutions to support diagnosis, commenting that digital innovation is already part of clinical practice in respiratory medicine. Digital spirometry can provide useful information to clinicians and support clinical decision making while artificial intelligence has the potential to supplement human judgement for the benefit of patients.
Digital applications for current and future asthma management
Drawing on experience from the field of respiratory sleep medicine and progress made as a result of the COVID-19 pandemic, Dr Holger Woehrle (Germany) encourages us to realise that the future is digital, and that we should embrace it, work with it and discuss it so that it can be shaped to bring positive value to patients and physicians.
Panel discussion
Joining together for a final discussion, the panel explore issues raised by the symposium content and remind us that while asthma and COPD deaths are on the rise, digital solutions could and should be part of the solution and are something we all need to embrace.
Faculty Q&A
Following the Digital Symposium, the panel came together to answer and discuss key questions submitted by attendees at the ERS International Congress 2020 Virtual. Discover more on a wide range of topics, from how digital interventions are assessed in clinical trials to the potential benefits of individual digital tools.
Webinars
Explore this section of the learning zone for asthma related spotlight webinars!
GINA 2021 Spotlight Webinar
This webinar provides a concise review of the updated GINA 2021 strategy recommendations and the implications for clinical practice. The review is followed by an interactive Q&A session with physicians from across the world.
Expert faculty:
Dr Mark Levy, United Kingdom
Professor van Zyl-Smit, South Africa
What’s new in GINA 2021?
Content produced in June 2021.
Implications for your clinical practice
Content produced in June 2021.
Live Q&A session with the faculty
Content produced in June 2021.
Digital innovations in respiratory care
Welcome to the 2019 Spotlight Webinar on digital innovations in respiratory care. The webinar provides an overview of the current unmet needs and goals of inhalation therapies and how digital innovations could help achieve these inhalation treatment goals. The review is followed by an interactive Q&A session with physicians from across the world.
Faculty: Professor David Price and Professor Richard Costello
How digital innovations could help achieve inhalation treatment goals
Content produced in November 2019.
The current unmet needs and goals of inhalation therapies
Content produced in November 2019.
Live, interactive Q&A with the audience worldwide
Content produced in November 2019.
Explore this section of the zone for various infographics, including downloadable and printable versions.
Resource from the PLATINUM clinical programme
View these animated infographics which provide an overview of IRIDIUM, ARGON, PALLADIUM AND QUARTZ, the four studies that make up the PLATINUM clinical programme. Learn about the LABA/LAMA/ICS and LABA/ICS combinations investigated in this programme, as well as the purpose, patients, endpoints and key results for each study.
The PLATINUM program was also discussed at the Novartis-sponsored Inhaled Symposium ERS 2020.
Content produced in September 2020.
Infographic – Digital and drug delivery innovations to improve adherence in asthma
Download and print this infographic to learn more about the reasons for poor adherence in patients with asthma and the drug delivery and digital innovations that can be used to address and improve poor adherence.
Content produced in May 2020.
Expert opinion
Explore this section of the zone for expert opinion interviews, podcasts and videos!
The IRIDIUM study
Professor David Halpin discusses the IRIDIUM Phase III study and its implications for clinical practice.
Content produced in July 2020.
The ARGON study
Professor Claus Vogelmeier discusses the ARGON Phase III study and its implications for clinical practice.
Content produced in July 2020.
The PALLADIUM study
Professor Richard van Zyl-Smit discusses the PALLADIUM Phase III study and its implications for clinical practice.
Content produced in July 2020.
Patient experience of asthma
Professor Christine Jenkins discusses the patient experience of asthma, including the burden of disease and treatment, and how this can be improved through patient-physician communication and shared decision making.
Content produced in August 2020.
Podcast: The IRIDIUM study
Professor David Halpin discusses the clinical implications of the IRIDIUM Phase III trial in patients with asthma uncontrolled on LABA/ICS.
Content produced in July 2020.
Podcast: Patient experience of asthma
Professor Christine Jenkins discusses the key challenges faced by patients with asthma and how clinicians can better support these patients.
Content produced in August 2020.
Podcast: The burden of asthma exacerbations
Dr Kai Beeh discusses the ongoing burden of asthma exacerbations and the recommendations for preventing and managing them.
Content produced in July 2020.
Podcast: Managing patients remotely
Professor Alan Kaplan discusses the advantages, challenges and tools involved in managing patients remotely.
Content produced in July 2020.
Unmet needs in asthma podcast: why do patients remain uncontrolled? – Professors Claus Vogelmeier and Roland Buhl
In this podcast, Professor Vogelmeier and Professor Buhl discuss why many patients with asthma are uncontrolled, the impact this may have on patients and the implications for treatment.
Content produced in February 2020.
The unmet needs in asthma therapy: why do patients remain uncontrolled – Dr Kai Beeh
In this short video, Dr Kai Beeh reviews the key unmet needs in patients with asthma, with a focus on why patients may be uncontrolled on current therapy and how this can be addressed.
Content produced in March 2020.
Exacerbations: a deep dive – Professor Ken Chapman
Professor Chapman reviews the burden, mechanisms and interventions associated with exacerbations in patients with asthma.
Content produced in March 2020.
Uncontrolled asthma – Professor Klaus Rabe
Professor Klaus Rabe reviews the burden of uncontrolled asthma and what physicians need to know when diagnosing and treating patients with uncontrolled asthma.
Content produced in September 2019.
Assessing asthma control – Professor Christian Domingo
Professor Christian Domingo discusses the different perceptions patients and physicians may have when it comes to asthma control and how this should be addressed when assessing a patient’s control of their disease.
Content produced in September 2019.
The digital future – Professor Christian Domingo
Professor Christian Domingo discusses how increased use of digital innovations may improve asthma control and adherence.
Content produced in September 2019.
Digital devices in asthma – Professor Klaus Rabe
Professor Klaus Rabe discusses the potential uses of digital devices in asthma and how they can improve patient care.
Content produced in September 2019.
Reconsidering the potential of inhaled therapies in asthma: Novartis Virtual Asthma Theatre
Welcome to this exciting symposium, originally scheduled to take place at the American Thoracic Society (ATS) Conference 2020 and now made available to you via Medthority as a series of short videos.
These videos are intended for non-US healthcare professionals only.
Led by respiratory disease experts Professor David Price (chair), Professor Claus Vogelmeier and Professor Ken Chapman, learn how despite clinical advances reducing the number of asthma-related deaths, significant unmet needs remain. Treatment mismatch, poor adherence, and treatment misuse all contribute to the problem of uncontrolled asthma.
Given this context, you’ll be encouraged to reconsider the potential of inhaled therapies in the management of asthma, focussing on the treatment opportunity afforded by new inhaled, once-daily fixed-dose combinations. The scope for new devices and digital solutions to further improve treatment use and adherence in the asthma arena is also discussed. Finally, our faculty take a deep dive into some key management questions in a 10-minute Q&A session.
Introduction to the PLATINUM program
Professor Price describes the unmet need in asthma, highlighting that more than one-third of patients remain uncontrolled despite treatment. Professor Price goes on to introduce two new once-daily, inhaled fixed-dose combinations for asthma: indacaterol acetate and mometasone furoate (IND/MF); and indacaterol acetate, glycopyrronium bromide, and mometasone furoate (IND/GLY/MF).
A new LABA/ICS – a new treatment opportunity
Professor Vogelmeier shares data from the PALLADIUM trial, a 52-week, randomised double-blind, Phase III study. The study was primarily designed to compare IND/MF with MF and also included the active comparator salmeterol/fluticasone propionate (SAL/FLU) in secondary analyses.
Reconsidering the potential of inhaled therapies with a new, once-daily, fixed LAMA/LABA/ICS combination [Part 1]
Professor Vogelmeier presents results from the Phase III IRIDIUM study, a 52-week, randomised, double-blind trial assessing IND/GLY/MF against IND/MF (primary endpoint) or high-dose SAL/FLU (secondary endpoints) in patients with asthma, with a key focus on comparisons between IND/GLY/MF and IND/MF.
Reconsidering the potential of inhaled therapies with a new, once-daily, fixed LAMA/LABA/ICS combination [Part 2]
Professor Chapman reviews further data from the IRIDIUM trial comparing IND/GLY/MF with SAL/FLU for key efficacy and safety endpoints. Professor Chapman goes on to discuss the results of the Phase III ARGON trial, a 24-week, randomised, partially-blinded, non-inferiority study of IND/GLY/MF versus the free combination of SAL/FLU plus tiotropium (TIO) in its soft mist inhaler formulation.
Could a new device improve treatment use and adherence?
Professor Chapman considers features of the BREEZHALER® device which may help address poor inhaler technique among patients and discusses the role of the Propeller Sensor device, which may be attached to the BREEZHALER® device, to support therapeutic decision making.
Could digital solutions improve virtual consultations?
Professor Price provides an overview of the contribution of telemedicine, particularly in an era where the COVID-19 pandemic has highlighted the important role that virtual consultations can play in everyday clinical practice in asthma.
Concluding remarks
Professor Price provides final remarks on the evidence presented in the preceding videos. He summarises the clinical value of IND/GLY/MF and IND/MF, delivered via the BREEZHALER® device, and reflects on how these inhaled fixed-dose combinations should be used in clinical practice to help address unmet need in asthma.
Q&A
Last but not least, join Professors Price, Vogelmeier and Chapman for this interactive session as they take a deep dive into key questions in asthma management, raised by the issues discussed in previous presentations.
of interest
are looking at
saved
next event
Developed by EPG Health for Medthority in collaboration with Novartis Pharma AG, with content provided by Novartis Pharma AG.
Adherence infographic: MLR ID: 140215, FUSE ID: 76253. Webinars - Digital spotlight: MLR ID: 140226, FUSE ID: 76260. Expert opinion - uncontrolled asthma: MLR ID: 140229, FUSE ID: 76262. Expert opinion - assessment of asthma control: MLR ID: 140235, FUSE ID: 76342. Expert opinion - digital future: MLR ID: 140236, FUSE ID: 76266. Expert opinion - digital devices: MLR ID: 140241, FUSE ID: 76271. Talking Heads (GtL) Beeh: MLR: 148711, FUSE ID: 89695. Talking Heads (GtL) Chapman: MLR ID: 148713, FUSE ID: 89697. Unmet need podcast - Germany audio: MLR ID: 148717, FUSE ID: 89699. Platinum Animation: MLR ID: 148719, FUSE ID: 89772. ERS 2021 symposium recording Part 1 - 'Inhaled Therapy Science': MLR ID: 140220, FUSE ID: 76336. Supporting text: MLR ID: 156537, FUSE ID: 101263. Digital symposium ERS 2020: MLR ID: 148722, FUSE ID: 89803. Virtual Asthma Theatre meeting recording: MLR ID: 160905, FUSE ID: 107724. ERS 2022: FUSE ID: 256103.